For example, a suitable scaffold could potentially provide a more favorable surface for cell attachment or help maintain an environment in which useful biological signals remain available.
It might also offer mechanical support while the tissue undergoes its natural healing processes.
However, a scaffold alone does not automatically generate new, fully functional heart muscle. Researchers must establish whether any observed improvement comes from changes in tissue structure, reduced damage, altered inflammation, enhanced survival of existing cells, genuine regeneration, or a combination of these effects.
The distinction matters because a heart that pumps better after treatment has not necessarily regenerated all the muscle cells it previously lost.
Determining the actual mechanism will be an important part of the research.
From Laboratory Experiments to Animal Studies
The development of a new medical treatment is a long process, and Ferrer's project is still moving through its early stages.
According to a July 2026 profile published by Universidad Favaloro, Ferrer is a biology graduate and doctoral researcher associated with the university's cardiovascular regenerative medicine laboratory.
The university identifies her as part of a team working on the design of a bioactive hydrogel intended to help the heart after a heart attack.
A subsequent report by La Nación, published on August 20, 2026, described the project as having progressed from cell-based studies to preclinical animal testing.
That represents an important stage in the development process.
Laboratory experiments allow scientists to investigate how a material behaves under controlled conditions. They can examine its compatibility with cells, study its physical properties, and identify possible biological effects.
But laboratory results cannot answer every question about what happens inside a living organism.
Once a promising formulation has been developed, researchers need to examine how it behaves in the body, whether it remains where it is intended to act, how surrounding tissues respond, and whether it causes unexpected complications.
The heart presents additional challenges because it contracts continuously, conducts electrical signals, and is exposed to constant blood flow.
A material intended for this environment must be compatible with these demanding conditions.
According to the August report, Ferrer's team has tested its development in sheep, with preliminary observations reported over a 28-day period. The project remains preclinical, meaning it has not yet established safety and effectiveness through clinical trials in human patients.
Animal studies can help scientists understand biological responses and identify possible safety problems. Larger animals can also provide useful information about procedures and physiological conditions that may be difficult to reproduce in smaller models.
Even so, results in animals cannot reliably predict every aspect of a treatment's performance in humans.
Differences in anatomy, immune responses, disease progression, and healing can influence outcomes. A treatment that produces encouraging results in a laboratory or animal model may still fail to demonstrate meaningful benefits in people.
That is why the next stages of development are so important.
Why Clinical Trials Are Still Necessary
Before an experimental hydrogel can be used routinely in hospitals, researchers must answer a series of difficult questions.
Is the material safe when injected into the heart?
Does it remain stable for an appropriate period, or does it break down too quickly?
Can it be delivered precisely to the intended location?
Does it interfere with the heart's electrical activity or normal contraction?
Could it trigger inflammation, an immune reaction, or other unwanted effects?
And, most importantly, does it improve outcomes that matter to patients?
These questions cannot be answered by enthusiasm alone.
Clinical trials are designed to evaluate investigational treatments in people through structured stages of testing, with appropriate oversight and informed consent.
Early-phase studies generally focus on safety, tolerability, and how a treatment behaves in the human body. Later studies may examine effectiveness, compare outcomes with existing care, and investigate less common adverse effects.
The process can take years, and there is no guarantee that a promising experimental treatment will ultimately receive approval.
In the case of Ferrer's hydrogel, the August 2026 reporting described regulatory preparation as a future step and suggested that the first clinical studies could still be roughly two years away, depending on progress.
That timeline is an estimate, not a confirmed date for treatment availability.